Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01141504 · ClinicalTrials.gov registry record · Phase 1
Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance
A Phase 1 study of Healthy Subjects, sponsored by Metabolic Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT01141504 is a Phase 1 study of Healthy Subjects that has completed, run by Metabolic Technologies. The registered enrollment target is 16 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01141504, a Phase 1 study of Healthy Subjects, has completed, sponsored by Metabolic Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
Adenosine-triphosphate (ATP) serves as the sole energy source for muscle contraction. Therefore human performance of brief maximal exercise is limited, in part, by the availability of ATP to the contracting muscle. Because muscle ATP storage is small (enough to sustain maximal exercise for less than 1 second), factors that enhance either storage or resynthesis of ATP may have a positive impact on repeated muscle contractions. The current study will test the hypothesis that increasing ATP availability to muscle via oral supplementation will improve performance of repeated high intensity exercise as measured by a) work performed in each of the three 50 contraction fatigue tests, b) sum of total work performed, and c) percentage decrement in total work from the first to third third 50 contraction test.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT PeakATP 250
- DIETARY_SUPPLEMENT PeakATP 400
- DIETARY_SUPPLEMENT PeakATP 400 plus proprietary blend
Study Locations (1)
Iowa
- Iowa State University - Ames
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01141504
The ClinicalTrials.gov registry entry for NCT01141504 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (87% lower). The listed sponsor is Metabolic Technologies, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01141504 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT01141504 about?
NCT01141504 is a clinical study titled "Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance". Adenosine-triphosphate (ATP) serves as the sole energy source for muscle contraction. Therefore human performance of brief maximal exercise is limited, in part, by the availability of ATP to the contracting muscle. Because muscle ATP storage is small (enough to sustain maximal exercise for less than...
What is the current status of trial NCT01141504?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2010-06. Estimated completion is 2011-10.
What conditions does trial NCT01141504 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT01141504?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), PeakATP 250 (DIETARY_SUPPLEMENT), PeakATP 400 (DIETARY_SUPPLEMENT), PeakATP 400 plus proprietary blend (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01141504?
This trial is sponsored by Metabolic Technologies, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01141504 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.